Devyser welcomes Fredrik Alpsten as new CEO starting September 1st. Ulf Klangby, the former CEO and founder of Devyser, continues as COO and board member of Devyser.
Fredrik Alpsten has more than 25 years of experience from executive positions within the life science industry, mainly at listed companies. His experience includes six years as Group CFO at Boule Diagnostics, listed at the Nasdaq Stockholm main list, and CEO of Boule Diagnostics’ US subsidiary Clinical Diagnostic Solutions Inc. Previous positions also include CFO and Deputy CEO at the listed medical device company IRRAS, and most recently, CFO at the clinical stage pharmaceutical company AlgiPharma.
Fredrik Alpsten holds a Bachelor of Science Degree from Stockholm School of Economics.
”I am very excited to take on this challenge with Devyser. The company has a highly competitive product portfolio and R&D pipeline paired with a strong sales growth and a scalable business model. The rapid advancements of DNA sequencing technology have opened up major market opportunities for highly precise diagnostics and Devyser has the prerequisites to be a key player in this segment. I am also looking forward to working closely with Ulf Klangby and the rest of the team who have created a fantastic company,” says Fredrik Alpsten, newly appointed CEO of Devyser.
”We are delighted to have Fredrik joining Devyser. Fredrik’s solid experience in building growth companies and his competence within financing and investor relations will be highly valuable when Devyser is entering the next phase of its development. His previous experience from diagnostic companies and the international arena will also be an important contribution when Devyser continues to expand on existing and new markets globally,” says Ulf Klangby, former CEO and founder of Devyser.
Link to the press release (in Swedish) here